Full-Time
Sanofi
10,001+ employees
Develops pharmaceuticals and vaccines globally
No salary listed
Mid, Senior
Hyderabad, Telangana, India
- 2 to 6 years of experience in creation of HTML emailers and Web graphic design
- Must have creative knowledge in Photoshop for Layout, HTML5, CSS3, JavaScript, Responsive website designing (Bootstrap) and creating approved email templates, creating approved email fragments in Veeva Vault
- Should be able to understand existing code and fix code issues
- Should have knowledge of W3C validation, Google page speed and email campaigning
- Should be proficient with the graphics tools like Adobe Photoshop, Adobe Illustrator, Adobe InDesign, Adobe Dreamweaver and Microsoft PowerPoint
- Ability to think creatively, aesthetically, independently and having good knowledge on all the graphic and current design trends
- Experience / knowledge following brand guidelines while working on deliverables and preparing templates
- Strong organizational and time management skills to effectively manage completing work activities
- Good communication skills both verbal and written
- Should be able to communicate clearly and effectively
- Graduate or postgraduate in any stream. Primarily in graphic design or art with focus on visualization of scientific content
- Excellent knowledge of English language (spoken and written)
- Design and develop web-based components in Veeva Vault, HTML5, CSS and JavaScript from the ground up as per the provided guidelines and specifications
- Maintain effective relationships with Content Enhancement team and Scientific Writers in SBO (and globally stakeholders, based on the project requirement)
- Work on business-critical deliverables, primarily on HTML Emailers/static web pages following the provided guidelines
- Extend support to work on digital and interactive deliverables (slide decks, scientific posters, newsletters, annual reports, patient education materials and other deliverables) based on the need
- Collaborate primarily with other graphic designers and SBO Scientific Writers to understand better on received project specific requirements and deliver the received requests on agreed time with good quality
- Provide technical support and guidance to other graphic designers, when needed
- Proactively communicating and flagging issues to Project Manager on project timelines, any issues with the inputs received from Scientific Writers
- Prioritize and manage assigned projects; adhering to the defined quality and delivering on time following the provided specifications from the stakeholder
- Designing and setting up new templates adhering to brand guidelines and manage the continuity
- Actively participate in team meetings and provide suggestions based on the need for the team
- Sharing best practices or any new learnings to the team
- Showing flexibility to meet project demands to deliver the output on-time
- Upskill to enhance the content enhancement deliverables
- Indulge in self-learning in order to keep yourself updated with the latest developments in technologies required for the execution of work
- Desirable experience in pharmaceuticals / healthcare industry and scientific context mediation
Sanofi provides healthcare solutions through its pharmaceutical and biotechnology products, focusing on treatments and vaccines for various medical needs. The company conducts extensive research and development to create new therapies and improve existing ones, particularly in areas like immunology, oncology, and rare diseases. Sanofi's products include prescription medicines, over-the-counter items, and vaccines, which are distributed to patients, healthcare professionals, and governments. What sets Sanofi apart from its competitors is its strong emphasis on scientific innovation and strategic partnerships, allowing it to maintain a diverse product pipeline. The company's goal is to enhance health outcomes and improve the quality of life for people globally.
Company Size
10,001+
Company Stage
IPO
Headquarters
Paris, France
Founded
1973
Simplify's Take
What believers are saying
- Sanofi reported a 20% profit growth in Q1 2025, driven by new launches.
- Dupixent's approval for CSU expands its market presence in immunology.
- Tolebrutinib's potential approval could address unmet needs in multiple sclerosis.
What critics are saying
- Increased competition in immunology may impact Dupixent's market share.
- Potential EU regulatory delays could affect tolebrutinib's market entry.
- Dren Bio acquisition may pose integration challenges and financial strain.
What makes Sanofi unique
- Sanofi's Dupixent is the first targeted therapy for chronic spontaneous urticaria.
- Tolebrutinib is a novel brain-penetrant BTK inhibitor for multiple sclerosis.
- Sanofi's global reach allows it to navigate diverse regulatory environments effectively.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Professional Development Budget
Parental Leave
Company News
Innate Pharma announced a €15M investment by Sanofi, subscribing to 8,345,387 new shares at €1.7974 each. This capital increase supports their ongoing partnership, including the BCMA targeting ANKET® program. The investment will aid in extending Innate's cash runway for pipeline execution. The capital increase is expected to close on April 25, 2025, with shares trading on Euronext Paris the same day.
Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticariaApproval based on phase 3 studies demonstrating Dupixent significantly reduced itch and hives compared to placeboIn the US, there are more than 300,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite antihistamine treatmentCSU is the seventh disease with underlying type 2 inflammation in which Dupixent is approvedParis and Tarrytown, NY, April 18, 2025. The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adults and adolescents aged 12 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite histamine-1 (H1) antihistamine treatment.Kenneth MendezPresident and Chief Executive Officer at the Asthma and Allergy Foundation of America“People with chronic spontaneous urticaria experience sudden, unpredictable hives and severe itch that cause a significant, and often overwhelming, burden on their everyday lives. The approval of this treatment offers patients more options and the chance to control their disease.”Alyssa Johnsen, M.D., Ph.D.Global Therapeutic Area Head, Immunology and Oncology Development at Sanofi“CSU patients with uncontrolled disease experience highly burdensome itch and hives that can significantly disrupt daily living. This FDA approval provides a new treatment option to help address the underlying drivers of these severe and recurring signs and symptoms. Dupixent has the potential to improve outcomes for CSU patients who previously had limited treatment options.”The US approval is based on data from two phase 3 clinical studies, Study A (n=136) and Study C (n=148), which included biologic-naïve patients aged 12 years and older who were symptomatic despite the use of antihistamines and assessed Dupixent as an add-on therapy to standard-of-care antihistamines, compared to antihistamines alone. Both studies met their primary and key secondary endpoints with Dupixent demonstrating reductions in itch severity and urticaria activity (a composite of itch and hives) compared to placebo at 24 weeks
Sanofi SA (NASDAQ:SNY) reported Thursday a first-quarter 2025 business operating income of 2.9 billion euros ($3.06 billion), up 20.1% year over year and 18.7% in constant currency. The company reported first-quarter sales of 9.89 billion euros ($10.42 billion), beating the consensus of $9.77 billion. This was driven by launches, Dupixent, and favorable Beyfortus phasing. Sales increased 10.8% year over year and 9.7% on constant currency. U.S. sales were 4.66 billion and increased by 15.4%
Results from the HERCULES phase 3 study showed delay in disability progression in people living with non-relapsing secondary progressive multiple sclerosisTolebrutinib has the potential to be the first therapy to modulate immunologic drivers of chronic inflammation behind the blood–brain barrier, a key driver of disability accumulation in MSTolebrutinib is being evaluated under priority review in the US with a target action date of 28 September 2025; regulatory submission dossier is under review in the EU with a decision expected in Q1 2026Paris, April 8, 2025. The New England Journal of Medicine (NEJM) published positive results from the HERCULES phase 3 study demonstrating that tolebrutinib delayed disability progression in people with non-relapsing secondary progressive multiple sclerosis (nrSPMS), where there are currently no treatment options approved. These findings further support the differentiated mechanism of oral, brain-penetrant tolebrutinib, targeting disability progression independent of relapse activity. These results were first presented at the ECTRIMS conference on September 20, 2024 in Copenhagen, Denmark and further analyses were also presented today during the Clinical Trials Plenary Session at the 2025 Annual Meeting for the American Academy of Neurology (AAN) in San Diego, California.Robert Fox, MDVice Chair of Research at Cleveland Clinic’s Neurological Institute, Cleveland, Ohio, US, and chair of the HERCULES global steering committee“Tolebrutinib represents a new class of therapy for the treatment of multiple sclerosis. In this large phase 3 study, tolebrutinib was found to slow the progression of disability in a subset of multiple sclerosis for which we have no approved therapies – non-relapsing secondary progressive disease. The results of this study signal a new chapter in multiple sclerosis because we finally found a potential way to treat non-relapsing secondary progressive forms.”Dr Fox is a paid advisor to Sanofi for the HERCULES study.Erik Wallström, MD, PhDGlobal Head of Neurology Development“By targeting disability progression mechanisms behind the blood-brain barrier, tolebrutinib has the potential to be a practice-changing therapeutic option for people living with multiple sclerosis
If approved, tolebrutinib would be the first and only brain-penetrant BTK inhibitor to both treat non-relapsing secondary progressive multiple sclerosis (MS) and slow disability accumulation independent of relapse activityTolebrutinib has the potential to be the first therapy to target smoldering neuroinflammation, a key driver of disability accumulation in MSTolebrutinib was granted breakthrough therapy designation by the FDA based on positive results from the HERCULES phase 3 study in adults with non-relapsing secondary progressive MSParis, March 25, 2025. The US Food and Drug Administration (FDA) is evaluating under priority review the regulatory submission of tolebrutinib to treat non-relapsing secondary progressive multiple sclerosis (nrSPMS) and to slow disability accumulation independent of relapse activity in adult patients. The target action date for the FDA decision is September 28, 2025. A regulatory submission is also under review in the EU.The regulatory submissions in the US and the EU are supported by the results from the phase 3 studies HERCULES in nrSPMS and GEMINI 1 and 2 in relapsing MS (RMS). The findings from these studies, as well as additional clinical and preclinical studies, support the differentiated mechanism of tolebrutinib to target disability progression independent of relapse activity, and the scientific hypothesis that smoldering neuroinflammation represents a key inflammatory process in MS and is a critical driver of disability accumulation.Erik Wallström, MD, PhDGlobal Head of Neurology Development“The totality of data across our clinical program validates our scientific understanding of smoldering neuroinflammation as a distinct inflammatory process in MS. People living with non-relapsing secondary progressive multiple sclerosis or who experience disability independent of relapse activity suffer from disability that worsens over time due to persistent inflammation in the brain, known as smoldering neuroinflammation, which is the primary driver of disability